Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure.

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Current Hypertension Reviews Pub Date : 2023-01-01 DOI:10.2174/1573402119666230330082128
Selvia Mf Hanna, Hoda M Rabea, Mohamed Ea Abdelrahim, Hesham B Mahmoud
{"title":"Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure.","authors":"Selvia Mf Hanna,&nbsp;Hoda M Rabea,&nbsp;Mohamed Ea Abdelrahim,&nbsp;Hesham B Mahmoud","doi":"10.2174/1573402119666230330082128","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nebivolol has a dual mechanism of action, exerting a moderate b- blockade effect and reducing peripheral arterial resistance, as a result, the antihypertensive effect of nebivolol may be higher than that of a potent vasodilator CCB such as amlodipine.</p><p><strong>Aim: </strong>The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment. Ambulatory blood pressure monitoring is a powerful method to monitor the changes in blood pressure over the 24 hour.</p><p><strong>Materials and methods: </strong>A total of 74 from 90 patients continued the study. Fourty patients received amlodipine 10 mg/valsartan 160 mg (group I), and thirty-four patients received nebivolol 5 mg/ valsartan 160 mg (group II). Peripheral blood pressure readings were measured at randomization at 6 and 12 weeks. Ambulatory blood pressure was measured at randomization and 12 weeks.</p><p><strong>Results: </strong>Both drug combinations showed high efficacy in reducing peripheral and 24 hour ambulatory BP. There was no statistically significant difference between the groups in lowering peripheral systolic and diastolic blood pressure at 6 and 12 weeks. Furthermore, both groups failed to show any significant difference in reducing 24 hour SBP and DBP. Regarding day SBP, the blood pressure dropped by -5.63 ± 14.87 in group I and -6.25 ± 11.59 in group II (p = 0.844). Also, group I reduced the day DBP average by -2.53 ± 9.83 and group II by -3.61 ± 9.78 (p = 0.640). In addition, both drug combinations had no statistically significant difference in lowering night SBP and DBP average.</p><p><strong>Conclusion: </strong>Both treatment groups reached the target ambulatory blood pressure, and there was no statistically significant difference between both groups as a regard reduction in all ambulatory blood pressure readings.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573402119666230330082128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Nebivolol has a dual mechanism of action, exerting a moderate b- blockade effect and reducing peripheral arterial resistance, as a result, the antihypertensive effect of nebivolol may be higher than that of a potent vasodilator CCB such as amlodipine.

Aim: The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment. Ambulatory blood pressure monitoring is a powerful method to monitor the changes in blood pressure over the 24 hour.

Materials and methods: A total of 74 from 90 patients continued the study. Fourty patients received amlodipine 10 mg/valsartan 160 mg (group I), and thirty-four patients received nebivolol 5 mg/ valsartan 160 mg (group II). Peripheral blood pressure readings were measured at randomization at 6 and 12 weeks. Ambulatory blood pressure was measured at randomization and 12 weeks.

Results: Both drug combinations showed high efficacy in reducing peripheral and 24 hour ambulatory BP. There was no statistically significant difference between the groups in lowering peripheral systolic and diastolic blood pressure at 6 and 12 weeks. Furthermore, both groups failed to show any significant difference in reducing 24 hour SBP and DBP. Regarding day SBP, the blood pressure dropped by -5.63 ± 14.87 in group I and -6.25 ± 11.59 in group II (p = 0.844). Also, group I reduced the day DBP average by -2.53 ± 9.83 and group II by -3.61 ± 9.78 (p = 0.640). In addition, both drug combinations had no statistically significant difference in lowering night SBP and DBP average.

Conclusion: Both treatment groups reached the target ambulatory blood pressure, and there was no statistically significant difference between both groups as a regard reduction in all ambulatory blood pressure readings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
固定剂量组合氨氯地平/缬沙坦与两种药物组合奈比洛尔/缬沙坦对24小时动态血压的影响比较。
背景:奈比洛尔具有双重作用机制,具有中等的b-阻断作用和降低外周动脉阻力。因此,奈比洛尔的降压作用可能高于氨氯地平等强效血管舒张剂CCB。目的:本研究评估了与氨氯地平/缬沙坦相比,两种奈比洛尔/缬沙坦对II级或III级高血压患者24小时动态血压的影响,或尽管进行了治疗,但血压仍无法控制。动态血压监测是一种监测24小时内血压变化的强大方法。材料和方法:90名患者中的74人继续进行研究。40例患者接受氨氯地平10mg/缬沙坦160mg(I组),34例患者接受奈比洛尔5mg/缬沙坦160 mg(II组)。在随机分组的第6周和第12周测量外周血压读数。随机分组时和12周时测量动态血压。结果:两种药物组合均显示出降低外周血压和24小时动态血压的高效性。在6周和12周时,两组在降低外周收缩压和舒张压方面没有统计学上的显著差异。此外,两组在降低24小时收缩压和舒张压方面均未显示出任何显著差异。在第1天SBP方面,第1组的血压下降了-5.63±14.87,第2组的血压降低了-6.25±11.59(p=0.844)。此外,第1天DBP平均值下降了-2.53±9.83,第2天DBP均值下降了-3.61±9.78(p=0.640)。另外,两种药物组合在降低夜间SBP和DBP均值方面没有统计学显著差异。结论:两个治疗组都达到了目标动态血压,在所有动态血压读数的下降方面,两组之间没有统计学上的显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Hypertension Reviews
Current Hypertension Reviews PERIPHERAL VASCULAR DISEASE-
CiteScore
4.80
自引率
0.00%
发文量
26
期刊介绍: Current Hypertension Reviews publishes frontier reviews/ mini-reviews, original research articles and guest edited thematic issues on all the latest advances on hypertension and its related areas e.g. nephrology, clinical care, and therapy. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all clinicians and researchers in the field of hypertension.
期刊最新文献
Association of Angiotensin Converting Enzyme Phenotypes and Polymorphisms with Clinical Outcomes in SARS-CoV2 Patients with Hypertension in an Urban Emergency Department. Investigating the Effect of COVID-19 on Pregnancy-Induced Hypertension (HTN): A Case-Control Study. Polyphenol-Mediated Modulation of Non-Coding RNAs: A New Therapeutic Approach for Hypertension - A Review. Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods study. The New Editor-In-Chief Note.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1